Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74779

1.

Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation.

Horiuchi K, Asakura T, Sakaguchi S, Saito F.

BMJ Case Rep. 2019 Jun 21;12(6). pii: e229310. doi: 10.1136/bcr-2019-229310.

PMID:
31229973
2.

Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance Induced by Membranous/Cytoplasmic/Nuclear Translocation of Epidermal Growth Factor Receptor.

Rong X, Liang Y, Han Q, Zhao Y, Jiang G, Zhang X, Lin X, Liu Y, Zhang Y, Han X, Zhang M, Luo Y, Li P, Wei L, Yan T, Wang E.

J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30480-0. doi: 10.1016/j.jtho.2019.06.014. [Epub ahead of print]

PMID:
31228625
3.

Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer.

Wong SM, Almana N, Choi J, Hu J, Gagnon H, Natsuhara K, Shen AH, DeSantis S, Dominici L, Golshan M, Weiss A, Bellon J, Mittendorf EA, King TA.

Ann Surg Oncol. 2019 Jun 21. doi: 10.1245/s10434-019-07517-2. [Epub ahead of print]

PMID:
31228134
4.

Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).

Gibson MK, Catalano P, Kleinberg LR, Staley CA 3rd, Montgomery EA, Jimeno A, Song WF, Mulcahy MF, Leichman LP, Benson AB 3rd.

Oncologist. 2019 Jun 21. pii: theoncologist.2018-0750. doi: 10.1634/theoncologist.2018-0750. [Epub ahead of print]

PMID:
31227647
5.

V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer.

Gao Y, Maria A, Na N, Da Cruz Paula A, Gorelick AN, Hechtman JF, Carson J, Lefkowitz RA, Weigelt B, Taylor BS, Zhao H, Reis-Filho JS, de Stanchina E, Rosen N, Yao Z, Yaeger R.

Cancer Discov. 2019 Jun 21. pii: CD-19-0356. doi: 10.1158/2159-8290.CD-19-0356. [Epub ahead of print]

PMID:
31227518
6.

Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.

Wei Q, Zhang Y, Gao J, Li J, Li J, Li Y, Zhou J, Lu M, Gong J, Zhang X, Shen L, Sun Y, Chang L, Wang X.

Clin Colorectal Cancer. 2019 May 13. pii: S1533-0028(19)30010-6. doi: 10.1016/j.clcc.2019.05.001. [Epub ahead of print]

PMID:
31227437
7.

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer.

Wang Q, Yang S, Wang K, Sun SY.

J Hematol Oncol. 2019 Jun 21;12(1):63. doi: 10.1186/s13045-019-0759-9. Review.

8.

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents.

Rachiglio AM, Lambiase M, Fenizia F, Roma C, Cardone C, Iannaccone A, De Luca A, Carotenuto M, Frezzetti D, Martinelli E, Maiello E, Ciardiello F, Normanno N.

Cancers (Basel). 2019 Jun 20;11(6). pii: E859. doi: 10.3390/cancers11060859.

9.

Enhanced Hepatogenic Differentiation of Human Wharton's Jelly-Derived Mesenchymal Stem Cells by Using Three-Step Protocol.

Panta W, Imsoonthornruksa S, Yoisungnern T, Suksaweang S, Ketudat-Cairns M, Parnpai R.

Int J Mol Sci. 2019 Jun 20;20(12). pii: E3016. doi: 10.3390/ijms20123016.

10.

Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with non-small cell lung cancer and brain metastases.

Lee CC, Hsu SPC, Lin CJ, Wu HM, Chen YW, Luo YH, Chiang CL, Hu YS, Chung WY, Shiau CY, Guo WY, Hung-Chi Pan D, Yang HC.

J Neurosurg. 2019 Jun 21:1-8. doi: 10.3171/2019.4.JNS19446. [Epub ahead of print]

PMID:
31226692
11.

Green synthesis of selenium-N-heterocyclic carbene compounds: Evaluation of antimicrobial and anticancer potential.

Kamal A, Nazari V M, Yaseen M, Iqbal MA, Ahamed MBK, Majid ASA, Bhatti HN.

Bioorg Chem. 2019 Jun 7;90:103042. doi: 10.1016/j.bioorg.2019.103042. [Epub ahead of print]

PMID:
31226469
12.

Western Diet-Induced Dysbiosis Is Associated with Intestinal Hyperplasia and Dysregulation of FXR-FGF19 Gene Expression in Juvenile Iberian Pigs (OR26-03-19).

Smith V, Hernandez G, Terkatz C, Meyer I, Rice M, Columbus D, Edwards M, Burd M, Sprayberry K, VanderKelen J, Steinhoff-Wagner J, Peterson D, Fanter R, Kitts C, Frano M, Burrin D, Maj M, Manjarin R.

Curr Dev Nutr. 2019 Jun 13;3(Suppl 1). pii: nzz033.OR26-03-19. doi: 10.1093/cdn/nzz033.OR26-03-19. eCollection 2019 Jun.

PMID:
31225016
13.

Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S.

Li Q, Zhang T, Li S, Tong L, Li J, Su Z, Feng F, Sun D, Tong Y, Wang X, Zhao Z, Zhu L, Ding J, Li H, Xie H, Xu Y.

ACS Med Chem Lett. 2019 May 22;10(6):869-873. doi: 10.1021/acsmedchemlett.8b00564. eCollection 2019 Jun 13.

PMID:
31223440
14.

QSAR modeling, pharmacophore-based virtual screening, and ensemble docking insights into predicting potential epigallocatechin gallate (EGCG) analogs against epidermal growth factor receptor.

Bommu UD, Konidala KK, Pabbaraju N, Yeguvapalli S.

J Recept Signal Transduct Res. 2019 Jun 21:1-10. doi: 10.1080/10799893.2018.1564151. [Epub ahead of print]

PMID:
31223050
15.

Correlation of demographic, histological and molecular characteristics and clinical course of the disease in patients with lung adenocarcinoma.

Novaković Lacković L, Latinović Tadić L, Stanetić M, Tanasković N, Marić S, Lacković M.

Med Glas (Zenica). 2019 Aug 1;16(2). doi: 10.17392/1003-19. [Epub ahead of print]

16.

The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice.

Engle DD, Tiriac H, Rivera KD, Pommier A, Whalen S, Oni TE, Alagesan B, Lee EJ, Yao MA, Lucito MS, Spielman B, Da Silva B, Schoepfer C, Wright K, Creighton B, Afinowicz L, Yu KH, Grützmann R, Aust D, Gimotty PA, Pollard KS, Hruban RH, Goggins MG, Pilarsky C, Park Y, Pappin DJ, Hollingsworth MA, Tuveson DA.

Science. 2019 Jun 21;364(6446):1156-1162. doi: 10.1126/science.aaw3145.

PMID:
31221853
17.

China National Medical Products Administration approval summary: anlotinib for the treatment of advanced non-small cell lung cancer after two lines of chemotherapy.

Zhou M, Chen X, Zhang H, Xia L, Tong X, Zou L, Hao R, Pan J, Zhao X, Chen D, Song Y, Qi Y, Tang L, Liu Z, Gao R, Shi Y, Yang Z.

Cancer Commun (Lond). 2019 Jun 20;39(1):36. doi: 10.1186/s40880-019-0383-7. Review.

18.
19.

Accuracy of Intraoperative Frozen Section of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy for Breast Carcinoma.

Grabenstetter A, Moo TA, Hajiyeva S, Schüffler PJ, Khattar P, Friedlander MA, McCormack MA, Raiss M, Zabor EC, Barrio A, Morrow M, Edelweiss M.

Am J Surg Pathol. 2019 Jun 18. doi: 10.1097/PAS.0000000000001311. [Epub ahead of print]

PMID:
31219817
20.

The effect of Oncotype DX® on adjuvant chemotherapy treatment decisions in early breast cancer.

Rabie MA, Rankin A, Burger A, Youssef M.

Ann R Coll Surg Engl. 2019 Jun 20:1-6. doi: 10.1308/rcsann.2019.0096. [Epub ahead of print]

PMID:
31219316

Supplemental Content

Loading ...
Support Center